keyword
MENU ▼
Read by QxMD icon Read
search

Aromatase inhibitors

keyword
https://www.readbyqxmd.com/read/29783894/fulvestrant-in-management-of-hormone-receptor-positive-metastatic-breast-cancer
#1
Maryam Nemati Shafaee, Matthew James Ellis
Fulvestrant is a steroidal selective estrogen receptor degrader that was approved by the US FDA in 2002 for treatment of ER-positive metastatic breast cancer (ER + MBC) post-progression on aromatase inhibitors. In 2016, the label was updated to include endocrine therapy naive ER + MBC. While initially fulvestrant was thought to be equivalent to aromatase inhibitors with monthly dose of 250 mg intramuscular injection, several postmarketing trials challenged this understanding. Subsequently, the recommended dose changed to 500 mg monthly plus loading dose, and this was proven to be superior to anastrozole in efficacy...
May 22, 2018: Future Oncology
https://www.readbyqxmd.com/read/29783185/impact-of-body-mass-index-on-the-efficacy-of-endocrine-therapy-in-patients-with-metastatic-breast-cancer-a-retrospective-two-center-cohort-study
#2
Luwam Zewenghiel, Henrik Lindman, Antonis Valachis
BAKGROUND: The aim of this study was to investigate the impact of body mass index (BMI) on the efficacy of endocrine therapy in postmenopausal women with metastatic hormone receptor breast cancer (HR+BC) as well as to identify if the potential difference in efficacy was associated with Fulvestrant only or both aromatase inhibitors (AIs) and Fulvestrant. METHODS: A consecutive cohort of postmenopausal women with HR+metastatic breast cancer that have received endocrine therapy including Fulvestrant as a metastatic treatment strategy at the Departments of Oncology in Eskilstuna and Uppsala, Sweden, between 2008 and 2016 were identified...
May 18, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29781326/progression-free-survival-with-endocrine-based-therapies-following-progression-on-non-steroidal-aromatase-inhibitor-among-postmenopausal-women-with-hr-her2-metastatic-breast-cancer-a-network-meta-analysis
#3
Rajeev Ayyagari, Derek Tang, Oscar Patterson-Lomba, Zhou Zhou, Jipan Xie, David Chandiwana, Anand A Dalal, Polly Ann Niravath
OBJECTIVE: To quantify the comparative efficacy of currently available endocrine-based therapies (ETs) for postmenopausal women with HR+/HER2- mBC after NSAI progression. DESIGN: network meta-analysis (NMA) Methods: Randomized clinical trials of ETs for HR+/HER2- mBC were identified via a systematic literature review using Medline, EMBASE, Cochrane Library, and key conference proceedings. All trials met the following inclusion criteria: 1) included women with HR+/HER2- mBC, 2) previous treatment with ETs or chemotherapy as first-line therapy, 3) treatment with ET as monotherapy or in combination with targeted therapy, 4) PFS was reported, and 5) published in 2007 (when HER2 testing became standardized) or later...
May 21, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29775928/tributyltin-impaired-reproductive-success-in-female-zebrafish-through-disrupting-oogenesis-reproductive-behaviors-and-serotonin-synthesis
#4
Wei-Yang Xiao, Ying-Wen Li, Qi-Liang Chen, Zhi-Hao Liu
Tributyltin (TBT), an organotin acting as aromatase (Cyp19a1) inhibitor, has been found to disrupt gametogenesis and reproductive behaviors in several fish species. However, few studies addressing the mechanisms underlying the impaired gametogenesis and reproduction have been reported. In this study, female adults of zebrafish (Danio rerio) were continuously exposed to two nominal concentrations of TBT (100 and 500 ng/L, actual concentrations: 90.8 ± 1.3 ng/L and 470.3 ± 2.7 ng/L, respectively) for 28 days...
May 12, 2018: Aquatic Toxicology
https://www.readbyqxmd.com/read/29772457/in-vitro-and-in-vivo-metabolic-investigation-of-the-palbociclib-by-uhplc-q-tof-ms-ms-and-in-silico-toxicity-studies-of-its-metabolites
#5
Balasaheb B Chavan, Shristy Tiwari, Shankar G, Rakesh D Nimbalkar, Prabha Garg, Srinivas R, M V N Kumar Talluri
Palbociclib (PAB) is a CDK4/6 inhibitor and U. S Food and Drug Administration (FDA) granted regular approval for the treatment of hormone receptor (HR) positive, metastatic breast cancer in combination with an aromatase inhibitor in postmenopausal women. Metabolite identification is a crucial aspect during drug discovery and development as the drug metabolites may be pharmacologically active or possess toxicological activity. As there are no reports on the metabolism studies of the PAB, the present study focused on investigation of the in vitro and in vivo metabolic fate of the drug...
May 14, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29769099/circulating-esr1-mutations-at-the-end-of-aromatase-inhibitor-adjuvant-treatment-and-after-relapse-in-breast-cancer-patients
#6
Violette Allouchery, Ludivine Beaussire, Anne Perdrix, David Sefrioui, Laetitia Augusto, Cécile Guillemet, Nasrin Sarafan-Vasseur, Frédéric Di Fiore, Florian Clatot
BACKGROUND: Detection of circulating ESR1 mutations is associated with acquired resistance to aromatase inhibitor (AI) in metastatic breast cancer. Until now, the presence of circulating ESR1 mutations at the end of adjuvant treatment by AI in early breast cancer had never been clearly established. In this context, the aim of the present study was to evaluate the circulating ESR1 mutation frequency at the end of adjuvant treatment and after relapse. METHODS: This monocentric retrospective study was based on available stored plasmas and included all early breast cancer patients who completed at least 2 years of AI adjuvant treatment and experienced a documented relapse after the end of their treatment...
May 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29765929/gonadotropin-releasing-hormone-agonist-plus-aromatase-inhibitor-in-the-treatment-of-uterine-leiomyoma-in-near-menopause-patient-a-case-series-study
#7
Sanam Moradan
Objectives: There are many drugs for of symptomatic fibroids. Gonadotropin-releasing hormone (GnRH) agonists are the well known drugs. Also, aromatase inhibitors are effective. All published studies surveyed the effect of one of these two drugs. In this study as the first study decided to evaluate the effectiveness of the combination of GnRH agonists + aromatise inhibitor on the uterine fibroids. Methods: A cross-sectional prospective case series study was performed on 10 known cases of uterine fibroids late perimenopause, at least 3 myomas >5 cm, abnormal uterine bleeding and anemia due to fibroids, candidate for hysterectomy, no tendency to surgery...
April 2018: Journal of Menopausal Medicine
https://www.readbyqxmd.com/read/29765553/acquired-resistance-to-everolimus-in-aromatase-inhibitor-resistant-breast-cancer
#8
Mariko Kimura, Toru Hanamura, Kouki Tsuboi, Yosuke Kaneko, Yuri Yamaguchi, Toshifumi Niwa, Kazutaka Narui, Itaru Endo, Shin-Ichi Hayashi
We previously reported the establishment of several types of long-term estrogen-depleted-resistant (EDR) cell lines from MCF-7 breast cancer cells. Type 1 EDR cells exhibited the best-studied mechanism of aromatase inhibitor (AI) resistance, in which estrogen receptor (ER) expression remained positive and PI3K signaling was upregulated. Type 2 EDR cells showed reduced ER activity and upregulated JNK-related signaling. The mTOR inhibitor everolimus reduced growth in cells similar to Type 1 EDR cells. The present study generated everolimus-resistant (EvR) cells from Types 1 and 2 EDR cells following long-term exposure to everolimus in vitro ...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29758407/synthesis-and-molecular-docking-of-n-n-disubstituted-thiourea-derivatives-as-novel-aromatase-inhibitors
#9
Ratchanok Pingaew, Veda Prachayasittikul, Nuttapat Anuwongcharoen, Supaluk Prachayasittikul, Somsak Ruchirawat, Virapong Prachayasittikul
A three series of thioureas, monothiourea type I (4a-g), 1,4-bisthiourea type II (5a-h) and 1,3-bisthiourea type III (6a-h) were synthesized. Their aromatase inhibitory activities have been evaluated. Interestingly, eight thiourea derivatives (4e, 5f-h, 6d, 6f-h) exhibited the aromatase inhibitory activities with IC50 range of 0.6-10.2 μM. The meta-bisthiourea bearing 4-NO2 group (6f) and 3,5-diCF3 groups (6h) were shown to be the most potent compounds with sub-micromolar IC50 values of 0.8 and 0.6 μM, respectively...
May 4, 2018: Bioorganic Chemistry
https://www.readbyqxmd.com/read/29755815/late-endobronchial-pulmonary-metastasis-in-a-patient-with-breast-cancer
#10
İbrahim Güven Çoşğun, Turgut Kaçan, Gül Erten
The lung is a common location for malignant metastases. However, endobronchial metastases from nonpulmonary neoplasms are rare. Metastatic breast cancer usually occurs in 2-3 years of the disease course. A 65-year-old woman visited our hospital for the evaluation of dry cough. The patient had a history of breast cancer, which was treated with modified radical mastectomy and axillary dissection 10 years ago; she was then treated with aromatase inhibitor for 5 years. Chest X-ray revealed right hilum enlargement...
April 2018: Turkish Thoracic Journal
https://www.readbyqxmd.com/read/29755596/phytochemicals-current-strategies-for-treating-breast-cancer
#11
REVIEW
Bridg'ette B Israel, Syreeta L Tilghman, Kitani Parker-Lemieux, Florastina Payton-Stewart
Females with early-stage metastatic, estrogen-dependent breast cancer are generally treated with surgery, radiation and chemotherapy, or with more targeted approaches such as aromatase inhibitors (anastrozole or letrozole) or anti-estrogens (tamoxifen). Despite widespread successful usage of these agents for the treatment of breast cancer, resistance, tumor relapse and metastasis remain the principal causes of mortality for patients with breast cancer. While numerous groups have made major contributions toward an improved understanding of resistance mechanisms, the currently insufficient grasp of the most critical pathways involved in resistance is evident in the inability to adequately treat and drastically improve patient outcomes in females with hormone-refractory breast cancer, including triple negative breast cancer...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29754304/impact-of-high-deductible-insurance-on-adjuvant-hormonal-therapy-use-in-breast-cancer
#12
Christine Y Lu, Fang Zhang, Anita K Wagner, Larissa Nekhlyudov, Craig C Earle, Matthew Callahan, Robert LeCates, Xin Xu, Dennis Ross-Degnan, J Frank Wharam
OBJECTIVE: High-deductible health plans (HDHPs) have become the predominant commercial health insurance arrangement in the US. HDHPs require substantial out-of-pocket (OOP) costs for most services but often exempt medications from high cost sharing. We examined effects of HDHPs on OOP costs and utilization of adjuvant hormonal therapy (AHT), which are fundamental care for patients with breast cancer. METHODS: This controlled quasi-experimental study used claims data (2003-2012) from a large national health insurer...
May 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29752687/a-phase-ii-study-evaluating-the-efficacy-of-zoledronic-acid-in-prevention-of-aromatase-inhibitor-associated-musculoskeletal-symptoms-the-zap-trial
#13
Cesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, Claire Snyder, Roisin M Connolly, John H Fetting, Daniel F Hayes, Stacie C Jeter, Robert S Miller, Anne Nguyen, Katie Quinlan, Gary L Rosner, Shannon Slater, Anna Maria Storniolo, Antonio C Wolff, Jane Zorzi, Nora Lynn Henry, Vered Stearns
PURPOSE: Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced incidence of AIMSS. METHODS: In the single-arm trial, the Zoledronic Acid Prophylaxis (ZAP) trial, we compared the incidence of AIMSS against historical controls from the Exemestane and Letrozole Pharmacogenomics (ELPh) trial...
May 11, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29752333/the-endocrinology-of-male-breast-cancer
#14
REVIEW
Ian S Fentiman
Male breast cancer (MBC) is a rare disease but, as a result of epidemiological collaborations, there is now greater clarity concerning endocrine risk factors. The significant rise in global age-standardised mean BMI in men is likely to lead to increases in incidence of maturity-onset diabetes and MBC. The metabolic changes accompanying obesity decrease androgens and sex hormone-binding globulin (SHBG), thereby increasing available oestrogens. The higher rates of MBC in North and Equatorial Africa are largely due to liver damage from endemic bilharziasis and hepatitis B causing elevated oestradiol (E2 ) levels from hepatic conversion of androgen...
June 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29747931/efficacy-of-different-leuprolide-administration-schedules-in-premenopausal-breast-cancer-a-retrospective-review
#15
Daniel C Kendzierski, Bryan P Schneider, Patrick J Kiel
BACKGROUND: Leuprolide is a safe and effective treatment of estrogen receptor-positive premenopausal breast cancer. Data from the SOFT/TEXT trials solidified leuprolide in combination with an aromatase inhibitor as an effective hormonal treatment for premenopausal breast cancer. However, the efficacy of monthly leuprolide depot compared to leuprolide depot every 3 months in combination with an aromatase inhibitor in this patient population is unclear. PATIENTS AND METHODS: In this single center retrospective study, 201 patients were enrolled between January 1, 2015, and October 1, 2016; 100 were included in the 7...
April 18, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29741296/assessment-and-management-of-bone-health-in-women-with-oestrogen-receptor-positive-breast-cancer-receiving-endocrine-therapy-position-statement-of-the-endocrine-society-of-australia-the-australian-and-new-zealand-bone-mineral-society-the-australasian-menopause
#16
Mathis Grossmann, Sabashini Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks, Helena Teede
OBJECTIVE: To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor-positive early breast cancer receiving endocrine therapy. METHODS: Representatives appointed by relevant Australian Medical Societies used a systematic approach for adaptation of guidelines (ADAPTE) to derive an evidence-informed position statement addressing five key questions. RESULTS: Women receiving adjuvant aromatase inhibitors and the subset of premenopausal woman on tamoxifen have accelerated bone loss and increased fracture risk...
May 9, 2018: Clinical Endocrinology
https://www.readbyqxmd.com/read/29739819/endoxifen-4-hydroxytamoxifen-and-an-estrogenic-derivative-modulate-estrogen-receptor-complex-mediated-apoptosis-in-breast-cancer
#17
Philipp Y Maximov, Balkees Abderrahman, Sean W Fanning, Surojeet Sengupta, Ping Fan, Ramona F Curpan, Daniela Maria Quintana Rincon, Jeffery A Greenland, Shyamala S Rajan, Geoffrey L Greene, V Craig Jordan
Estrogen therapy was used to treat advanced breast cancer in postmenopausal women for decades until the introduction of tamoxifen. Resistance to long-term estrogen deprivation (LTED) with tamoxifen and aromatase inhibitors used as a treatment for breast cancer inevitably occurs, but unexpectedly low dose estrogen can cause regression of breast cancer and increase disease free survival in some patients. This therapeutic effect is attributed to estrogen-induced apoptosis in LTED breast cancer. Here we describe modulation of the estrogen receptor liganded with antiestrogens (endoxifen, 4-hydroxytamoxifen) and an estrogenic triphenylethylene (TPE) EthoxyTPE (EtOXTPE) on estrogen-induced apoptosis in LTED breast cancer cells...
May 8, 2018: Molecular Pharmacology
https://www.readbyqxmd.com/read/29736566/the-impact-of-esr1-mutations-on-the-treatment-of-metastatic-breast-cancer
#18
REVIEW
Sasha M Pejerrey, Derek Dustin, Jin-Ah Kim, Guowei Gu, Yassine Rechoum, Suzanne A W Fuqua
After nearly 20 years of research, it is now established that mutations within the estrogen receptor (ER) gene, ESR1, frequently occur in metastatic breast cancer and influence response to hormone therapy. Though early studies presented differing results, sensitive sequencing techniques now show that ESR1 mutations occur at a frequency between 20 and 40% depending on the assay method. Recent studies have focused on several "hot spot mutations," a cluster of mutations found in the hormone-binding domain of the ESR1 gene...
May 7, 2018: Hormones & Cancer
https://www.readbyqxmd.com/read/29729786/oncology-acupuncture-for-chronic-pain-in-cancer-survivors-a-reflection-on-the-american-society-of-clinical-oncology-chronic-pain-guideline
#19
REVIEW
Weidong Lu, David S Rosenthal
Chronic pain syndromes associated with cancer treatment are common but difficult to manage. The American Society of Clinical Oncology recently published a practice guideline to address the unmet needs of cancer survivors, Management of Chronic Pain in Survivors of Adult Cancers, which stresses the importance of implementing integrative therapies including acupuncture. This review focuses on randomized clinical trials of acupuncture for chronic pain in cancer survivors, including its use in chemotherapy-induced peripheral neuropathy, aromatase inhibitor-associated arthralgia, and post neck dissection pain, and provides future directions of oncology acupuncture research in cancer survivorship...
June 2018: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/29726787/role-of-cyclin-dependent-kinase-4-6-inhibitors-in-the-current-and-future-eras-of-cancer-treatment
#20
S Parylo, A Vennepureddy, V Dhar, P Patibandla, A Sokoloff
Cyclin-dependent kinase 4/6 inhibitors, which act by inhibiting progression from the G1 to S phases of the cell cycle, include palbociclib, ribociclib, abemaciclib, and trilaciclib. Palbociclib and ribociclib are currently food and drug administration-approved for use in combination with aromatase inhibitors in postmenopausal women with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Palbociclib is also food and drug administration-approved for use in combination with fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer progressing after endocrine therapy...
January 1, 2018: Journal of Oncology Pharmacy Practice
keyword
keyword
117340
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"